SCHEMBL4803124

SCHEMBL4803124

O=C(Cc1ccccc1)Nc1ccccc1-c1cc[c]cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.58
GAA P10253 4/20 0.58
KMT2A Q03164 3/20 0.58
L3MBTL1 Q9Y468 3/20 0.58
MEN1 O00255 2/20 0.58
ALDH1A1 P00352 7/20 0.57
HPGD P15428 3/20 0.57
RAB9A P51151 1/20 0.55
SELL P14151 1/20 0.52
SELP P16109 1/20 0.52
SELE P16581 1/20 0.52
PARP14 Q460N5 1/20 0.51
MAPT P10636 2/20 0.50
KDM4E B2RXH2 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
EPHX2 P34913 1/20 0.50
HTT P42858 1/20 0.50
ATM Q13315 1/20 0.50
CASP3 P42574 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4802411 0.85 LMNA (0.54) LMNAGAAKMT2AL3MBTL1MEN1
SCHEMBL4803134 0.79 MEN1 (0.69) LMNAGAAKMT2AMEN1ALDH1A1
SCHEMBL694917 0.78 EPHX2 (0.76) LMNAGAAKMT2AL3MBTL1MEN1
SCHEMBL4629164 0.77 ALDH1A1 (0.75) LMNAGAAKMT2AL3MBTL1MEN1
SCHEMBL10804929 0.77 ALDH1A1 (0.55) LMNAKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL4629167 0.77 ALDH1A1 (0.57) LMNAGAAKMT2AL3MBTL1MEN1
SCHEMBL6164465 0.76 LMNA (0.64) LMNAGAAKMT2AL3MBTL1MEN1
SCHEMBL27875615 0.76 MEN1 (0.79) LMNAGAAKMT2AMEN1ALDH1A1
SCHEMBL28043487 0.74 EPHX2 (0.76) LMNAGAAKMT2AMEN1ALDH1A1
SCHEMBL23360743 0.74 CHRM3 (0.46) LMNAKMT2AL3MBTL1MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7427616-B2 Condensed pyridines and pyrimidines with tie2 (TEK) activity ASTRAZENECA AB (SE) 2008-09-23 US disclosed
EP-1537112-B1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2006-04-19 EP disclosed
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity ASTRAZENECA AB (SE) 2005-11-17 US disclosed
EP-1537112-A1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY Astrazeneca AB (SE) 2005-06-08 EP disclosed
WO-2004013141-A1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity TIE1, TEK, KDR LMNA 3041/4885GAA 4572/4885KMT2A 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.